All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Autoimmune Disease Therapies Market Booms as AbbVie's Skyrizi Poised to Become Second-Best Selling Drug

By

Amy Feldman

3h ago· 7 min readenNews

Summary

This article covers the booming market for autoimmune disease therapies, highlighting AbbVie's Skyrizi which is projected to become the world's second-biggest selling drug by 2032 with over $33 billion in revenue. It also touches on OpenAI's healthcare initiatives, Vertex's $10 billion acquisition of Crinetics, and other healthcare industry developments in this week's InnovationRx newsletter.

Source

bskyAutoimmune Disease Therapies Market Booms as AbbVie's Skyrizi Poised to Become Second-Best Selling Drugforbes.com

Key quotes

· 2 pulled
AbbVie's Skyrizi, an injectable drug for autoimmune diseases that include psoriasis and Crohn's disease, is expected to surpass $33 billion in revenue in 2032, making it the world's second-biggest selling drug
That puts it smack between Eli Lilly's GLP-1 blockbusters, Mounjaro (for diabetes) and Zepbound (for weight loss)
Snippet from the RSS feed
In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion purchase of Crinetics, and more.

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.